This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Ondansetron Treatment in Tourette’s Disorder: A 3-Week, Randomized, Double-Blind, Placebo-Controlled Study

Paz Toren, MD; Abraham Weizman, MD; Sharon Ratner, MD; Donald Cohen, MD; and Nathaniel Laor, MD, PhD

Published: April 15, 2005

Article Abstract

Objective: The aim of the present study was to evaluate the efficacy of ondansetron, a selective 5-HT3 antagonist, in the treatment of Tourette’s disorder.

Method: Participants (N = 30) aged 12 to 46 years, diagnosed with DSM-IV Tourette’s disorder and resistant to previous haloperidol treatment, were enrolled in a 3-week, randomized, double-blind, placebo-controlled outpatient study. Assessments were conducted at baseline and once a week during the study period. Scales used included the Tourette’s Syndrome Global Scale (TSGS), the Yale Global Tic Severity Scale (YGTSS), and the Yale-Brown Obsessive Compulsive Scale. Ondansetron dose was 8, 16, and 24 mg/day in the first, second, and third weeks, respectively.

Results: A significant positive effect of ondansetron on tic severity, as assessed by the TSGS, was noted (baseline vs. endpoint: mean ± SD = 29.62 ± 20.33 vs. 20.58 ± 12.82, p = .002 vs. placebo). However, no significant effect was detected upon assessing ondansetron/placebo effect on tic severity with the YGTSS (baseline vs. endpoint: mean ± SD = 24.04 ± 9.44 vs. 17.50 ± 9.48, p = .15 vs. placebo). No change in obsessive-compulsive symptoms was noted in either group. Adverse effects included mild and transient abdominal pain.

Conclusions: Ondansetron may have anti-tic effects in patients with Tourette’s disorder. Large-scale, double-blind studies should further assess the anti-tic efficacy of ondansetron.

Volume: 66

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF